Eqs-news.com
Tarus Therapeutics, Inc., acquires license to Adenosine Receptor
WebCorporate | 23 December 2019 12:00. Tarus Therapeutics Tarus Therapeutics, Inc., acquires license to Adenosine Receptor Antagonist Platform from Impetis Biosciences, Ltd.
Actived: 8 days ago
Top Categories
Popular Searched
› Cancer center orlando health
› Healthiest low sodium crackers
› Spring health psychiatrist jobs
› Munson healthcare virtual visit
› Chi health ne online payment
› Rapids regional women's health
› Providence health care santa rosa
› Washington state health insurance plan
› Pos recommendations for healthcare
Recently Searched
› Clinical mental health programs online
› Parkland health first provider portal
› Risk management in health care organizations
› Marion county health department vaccinations
› Orlando health reconstructive surgery
› Healthsprings prior authorization forms
› Ohio health pickerington methodist 2023
› Sacramento mental health resources